PM Modi chairs meeting to review India’s Covid-19 vaccination strategy


    PM Modi chairs fulfilling to evaluate India’s Covid-19 vaccination technique

    By: Express Web Desk|New Delhi |

    November 20, 2020 10: 26: 08 pm

    india covid vaccine, pm modi meeting india covid vaccine, coronavirus vaccination india, covid vaccine strategy india Prime Minister Narendra Modi at the evaluation meeting (Twitter/narendramodi)

    Prime Minister Narendra Modi Friday chaired a meeting to evaluate India’s method for Covid-19 vaccination and its subsequent delivery and circulation. Essential concerns related to the development of vaccine development, regulatory approvals and procurement were also discussed.

    Different concerns, consisting of the prioritisation of population groups, reaching out to health care employees, cold-chain facilities augmentation, adding vaccinators and tech platform for vaccine roll-out were also talked about in the conference, PM Modi stated.

    Held a meeting to evaluate India’s vaccination strategy and the way forward. Essential issues related to advance of vaccine development, regulative approvals and procurement were gone over.

    — Narendra Modi (@narendramodi) November 20, 2020

    Earlier in the day, Union Health Minister Harsh Vardhan said a digital platform used in the Universal Immunisation Program was being repurposed to digitally track motion of stocks of Covid-19 vaccines, as soon as available, and likewise trace those who will receive the shots therefore making sure last-mile vaccine delivery.

    The review meeting comes a day after Serum Institute of India (SII) CEO Adar Poonawalla stated the vaccine manufacturer will likely apply to India’s top drug regulator next month for e mergency approval for minimal use of ‘Covishield‘ on frontline employees and the elderly, which the vaccine, when authorized, could cost in between Rs 500 and Rs 600 in the private market for the public.

    Covishield, which is being produced by SII under an arrangement with Oxford-AstraZeneca, is the frontrunner in India’s own race to find a vaccine to beat the novel coronavirus

    Worldwide firms Pfizer and Moderna have also released interim outcomes of the late-stage trial of their mRNA vaccine prospects for Covid-19, showing an effectiveness rate of 95 per cent in volunteers without previous Covid-19 infection However, doses of these vaccines will not be available in quantities that can fulfil India’s immediate requirement. The government has, meanwhile, pinned its hopes on the 5 vaccine prospects that are being clinically tested here.

    ” Currently, phase-3 of vaccine prospect evaluated by Serum Institute is practically complete and the follow-up is currently under method. Bharat Biotech has just begun the phase-3 trials; Zydus Cadila has actually completed phase-2 trials, and Russian Sputnik -V being checked in cooperation with Dr Reddy will start phase two or three next week. Biological E is conducting an early stage 1-2 trial,” Dr V K Paul, member, NITI Aayog had actually said.

    The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the current headlines

    For all the most recent India News, download Indian Express App.

    ( the heading, this story has not been released by Important India News staff and is released from a syndicated feed.).


    Please enter your comment!
    Please enter your name here